You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Amid a flat month for the index, some firms saw large swings in their stock price. Natera led the gainers, while NantHealth led the decliners.
Going forward, the company will focus more on the global commercialization of its ePlex system and menu expansion.
The Index was up about 4 percent month over month and outpaced the Dow Jones Industrial Average and the Nasdaq Composite, but trailed the Nasdaq Biotechnology index.
With CE marking for the gram-positive and gram-negative panels, the firm has achieved the designation for its family of three ePlex bloodstream infection assays.
The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.
After announcing a $65 million public offering on Monday to fund commercialization efforts, the firm has increased the expected proceeds to $75 million.
The firm said that it intends to use the net proceeds from the offering for general corporate purposes and to fund its commercialization efforts.
The firm expects that revenues from ePlex installations at US customer sites will positively impact its financial results for the second half of 2017.
On the heels of obtaining CE marking for its BCID fungal panel, the firm expects to soon get US regulatory clearance for the ePlex instrument and RP panel.
The firm said that its CE-marked ePlex Blood Culture Identification fungal pathogen panel is the first of three tests that will become part of its sepsis solution.